Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388303 | 1.00 | NPSR1 (0.42) | NPSR1GAATDP1LMNAPOLB | |
| SCHEMBL3760199 | 0.98 | NPSR1 (0.41) | NPSR1GAATDP1LMNAPOLB | |
| SCHEMBL13856955 | 0.88 | ALDH1A1 (0.40) | NPSR1GAATDP1LMNAHTT | |
| SCHEMBL21761606 | 0.87 | LMNA (0.36) | NPSR1GAATDP1LMNAPOLB | |
| SCHEMBL21761734 | 0.87 | NPSR1 (0.37) | NPSR1GAATDP1LMNAPOLB | |
| SCHEMBL21761605 | 0.82 | LMNA (0.35) | NPSR1GAATDP1LMNAPOLB | |
| SCHEMBL21761736 | 0.82 | MAPK1 (0.38) | NPSR1GAATDP1LMNAALDH1A1 | |
| SCHEMBL13856952 | 0.79 | ALDH1A1 (0.44) | NPSR1GAATDP1LMNAHTT | |
| SCHEMBL3760193 | 0.73 | POLB (0.35) | NPSR1GAATDP1LMNAPOLB | |
| SCHEMBL15841319 | 0.73 | POLB (0.35) | NPSR1GAATDP1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012075591-A1 | IN VITRO MITOCHONDRIAL FUNCTION TEST (MFT) AND USES THEREOF | ARSENAULT ANDRE (CA) | 2012-06-14 | — | — | WO | claimed |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| US-12527885-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-01-20 | — | — | US | disclosed |
| WO-2025260130-A1 | COMPOUNDS AND USES THEREOF | THE UNIVERSITY OF MELBOURNE (AU) | 2025-12-26 | — | — | WO | disclosed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4591330-A2 | SOLID TARGET SYSTEMS FOR THE PRODUCTION OF HIGH-PURITY RADIONUCLIDE COMPOSITIONS | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
| EP-1670520-A4 | MINIATURIZED 62ZN/62CU GENERATOR FOR HIGH CONCENTRATION CLINICAL DELIVERY OF 62CU KIT FORMULATION FOR THE FACILE PREPARATION OF RADIOLABELED CU-BIS(THIOSEMICARBAZONE) COMPOUNDS | PROPORTIONAL TECHNOLOGIES INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060275208-A1 | Miniaturized 62zn/62cu generator for high concentration clinical delivery of 62cu kit formulation for the facile preparation of radiolabeled cu-bis(thiosemicarbazone)compounds | LACY JEFFREY L | 2006-12-07 | — | — | US | disclosed |
| EP-1670520-A2 | MINIATURIZED 62ZN/62CU GENERATOR FOR HIGH CONCENTRATION CLINICAL DELIVERY OF 62CU KIT FORMULATION FOR THE FACILE PREPARATION OF RADIOLABELED CU-BIS(THIOSEMICARBAZONE) COMPOUNDS | Proportional Technologies, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20060018827-A1 | Positron therapy of inflammation, infection and disease | MONTEFIORE MEDICAL CENTER | 2006-01-26 | — | — | US | disclosed |
| WO-2005084168-A2 | MINIATURIZED 62Zn/62Cu GENERATOR FOR HIGH CONCENTRATION CLINICAL DELIVERY OF 62Cu KIT FORMULATION FOR THE FACILE PREPARATION OF RADIOLABELED Cu-BIS(THIOSEMICARBAZONE) COMPOUNDS | PROPORTIONAL TECHNOLOGIES, INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| EP-0726077-B1 | Radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative | NIHON MEDIPHYSICS CO LTD (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-5843400-A | Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0726077-A2 | Radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative | NIHON MEDI-PHYSICS Co., Ltd. (JP) | 1996-08-14 | — | — | EP | disclosed |
| US-5079346-A | High uptake in heart, lipid soluble; myocardial perfusion imaging | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1992-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | NPSR1 4448/4885GAA 39/4885TDP1 3943/4885 |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | NPSR1 81/4885GAA 449/4885TDP1 3533/4885 |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | NPSR1 27/4885GAA 2433/4885TDP1 4783/4885 |
| US-12527885-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR1, PSMA1, KLK3 | NPSR1 107/4885GAA 266/4885TDP1 2926/4885 |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | FAP, SSTR1, PSMA1 | NPSR1 202/4885GAA 317/4885TDP1 1379/4885 |
| US-20060275208-A1 | Miniaturized 62zn/62cu generator for high concentration clinical delivery of 62cu kit formulation for the facile preparation of radiolabeled cu-bis(thiosemicarbazone)compounds | KIT, SLC30A6, SOD1 | NPSR1 2547/4885GAA 158/4885TDP1 3027/4885 |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | NPSR1 642/4885GAA 128/4885TDP1 4334/4885 |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR2, SSTR1, SSTR3 | NPSR1 61/4885GAA 2249/4885TDP1 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.